$NKTR

A roundup of Wall Street analyst actions on Wednesday includes Stifel upgrading DigitalOcean to buy, Truist upgrading CoreWeave to buy, and multiple initiations: Philip Morris at buy, Affirm at outperform, Nebius at outperform ($250 target), Digital Turbine at buy ($15), CoreWeave at outperform ($100), and DigitalOcean at outperform ($165). Wells Fargo raised Sandisk to equal weight with a $1,620 target; JPMorgan reiterated Shopify overweight. Other calls cover Disney, Fluence Energy, Vornado, a

ROBIN HOWARD W (President & CEO) sold 20,000 shares of NEKTAR THERAPEUTICS (NKTR) at an average of $60.75 ($59.97–$61.65, $1.22M total) across 4 trades over 2026-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000906709 0000906709 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor

The law firm Bronstein, Gewirtz & Grossman, LLC said it is investigating Nektar Therapeutics in connection with potential securities-related matters. The notice does not provide specific allegations or financial figures. The firm’s statement directs questions about the release to the company mentioned in the filing.

Nektar Therapeutics has entered a new equity distribution agreement with Guggenheim Securities and H.C. Wainwright, allowing it to sell up to $150 million in common stock to secure additional financing. Concurrently, interim CFO Sandra Gardiner is set to retire, with Linda Rubinstein stepping in to ensure continuity in financial leadership during this capital-raising period. Despite past financial weaknesses, Nektar has cash runway and positive sentiment from technicals and clinical milestones.

Nektar Therapeutics has entered into an Equity Distribution Agreement for an at-the-market offering of up to $150 million in common stock through Guggenheim Securities and H.C. Wainwright. Additionally, the company announced that interim CFO Sandra Gardiner will retire, and Linda Rubinstein of FLG Partners will take over as interim CFO and principal financial and accounting officer as of May 15, 2026. This 8-K filing details these capital markets and governance changes.

FMR LLC has filed an amended 13G disclosing a 15.0% beneficial ownership stake in Nektar Therapeutics (NASDAQ: NKTR), totaling 4,303,188.37 shares as of March 31, 2026. This stake includes holdings by Fidelity Growth Company Fund (5.6%) and Fidelity Growth Company Commingled Pool (6.5%). The filing indicates a passive investment approach, with FMR LLC possessing sole dispositive power over these shares.

A securities fraud lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) following a significant stock drop on December 16, 2025, when analysts flagged the inclusion of four ineligible patients in its REZOLVE-AA trial, causing it to miss its primary endpoint. Investors who purchased NKTR securities between February 26, 2025, and December 15, 2025, and incurred losses, may be able to recover compensation, with a lead plaintiff deadline set for May 5, 2026. Seven major Wall Street firms uniformly attributed the trial's failure and subsequent stock decline to these undisclosed enrollment violations, suggesting a direct causal link to investor harm.

Bernstein Liebhard LLP has filed a securities class action lawsuit against Nektar Therapeutics (NASDAQ: NKTR) on behalf of investors who purchased shares between February 26, 2025, and December 15, 2025. The lawsuit alleges that Nektar Therapeutics made misrepresentations regarding the Phase 2b trial for REZOLVE-AA. Shareholders who sustained losses are encouraged to contact Bernstein Liebhard LLP, with a lead plaintiff deadline of May 5, 2026.

Pomerantz LLP has filed a class action lawsuit against Nektar Therapeutics (NKTR) and certain officers, alleging federal securities law violations. The lawsuit, filed in the U.S. District Court for the Northern District of California, covers investors who purchased Nektar securities between February 26, 2025, and December 15, 2025. The firm claims Nektar made false and misleading statements regarding its REZOLVE-AA clinical trial for alopecia areata, specifically concerning enrollment protocol and the integrity of the trial results, which ultimately failed to meet statistical significance.